secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001437749-25-032076
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin granted Australian patent for Annamycin lyophilizate; term until 2040
-------------------------------------------------------------------------------

- Australian Patent No. 2024203598 covers preliposomal Annamycin lyophilizates with improved stability and high purity.
- Base patent term extends to June 2040, subject to extension for regulatory approval.
- Patent family includes issued U.S., allowed European, and expected Canadian patents.
- Annamycin (naxtarubicin) has Fast Track & Orphan Drug designations from FDA for AML and STS lung mets, and EMA Orphan Drug for AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925032076/0001437749-25-032076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925032076/mbrx20251028_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer